Get the Stockscreener App
1.2395
1.20%
-0.0105
Phio Pharmaceuticals Corp stock is traded at $1.2395, with a volume of 284.54K.
It is down -1.20% in the last 24 hours and down -42.82% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$1.25
Open:
$1.25
24h Volume:
284.54K
Relative Volume:
0.11
Market Cap:
$7.07M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.152
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
-13.64%
1M Performance:
-42.82%
6M Performance:
-32.51%
1Y Performance:
-48.11%
1-Day Range:
$1.20
$1.2867
1-Week Range:
$1.20
$1.40
52-Week Range:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.235 | 13.46M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.67 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.31 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.24 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
920.92 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
202.23 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
How Phio Pharmaceuticals Corp. (44R1) stock trades under stagflationMarket Activity Recap & AI Optimized Trade Strategies - newser.com
Published on: 2025-11-20 05:56:20 - newser.com
How Phio Pharmaceuticals Corp. stock performs in rate cut cyclesPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com
Is Phio Pharmaceuticals Corp. (44R1) stock protected from inflationJuly 2025 Analyst Calls & Low Risk Investment Opportunities - newser.com
How Phio Pharmaceuticals Corp. (44R1) stock reacts to fiscal policiesJuly 2025 Analyst Calls & Long-Term Growth Stock Strategies - newser.com
How Phio Pharmaceuticals Corp. (44R1) stock trades in high volatilityEarnings Summary Report & Accurate Entry/Exit Alerts - newser.com
How Phio Pharmaceuticals Corp. (44R1) stock reacts to new regulationsCEO Change & Fast Momentum Entry Tips - newser.com
Published on: 2025-11-19 20:52:55 - newser.com
How higher bond yields impact Phio Pharmaceuticals Corp. (44R1) stock2025 Support & Resistance & Short-Term High Return Ideas - newser.com
Published on: 2025-11-19 18:13:16 - newser.com
Published on: 2025-11-19 16:59:54 - newser.com
Published on: 2025-11-19 16:50:52 - newser.com
How Phio Pharmaceuticals Corp. (44R1) stock correlates with oil marketsDay Trade & Free Risk Controlled Daily Trade Plans - newser.com
Insider Buying: Robert Bitterman Acquires Additional Shares of Phio Pharmaceuticals Corp (PHIO) - GuruFocus
Bitterman buys Phio Pharmaceuticals (PHIO) stock worth $6350 By Investing.com - Investing.com Canada
Bitterman buys Phio Pharmaceuticals (PHIO) stock worth $6350 - Investing.com India
Why Phio Pharmaceuticals Corp. (44R1) stock appears on watchlists2025 Top Decliners & Step-by-Step Swing Trade Plans - newser.com
Why analysts maintain buy rating on Phio Pharmaceuticals Corp. (44R1) stockWeekly Trade Recap & Reliable Breakout Stock Forecasts - newser.com
Published on: 2025-11-19 01:14:18 - newser.com
Published on: 2025-11-19 01:03:35 - newser.com
Published on: 2025-11-19 00:18:12 - newser.com
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress - Newsfile
Phio Pharmaceuticals (NASDAQ: PHIO) to Present INTASYL siRNA at Advanced Therapies USA - Stock Titan
Will Phio Pharmaceuticals Corp. (44R1) stock profit from AI boomWeekly Trade Recap & High Conviction Investment Ideas - newser.com
Can Phio Pharmaceuticals Corp. hit a new high this monthBond Market & Safe Capital Growth Tips - newser.com
Is Phio Pharmaceuticals Corp. stock attractive for retirement portfoliosWeekly Stock Report & Safe Capital Growth Trade Ideas - newser.com
Is Phio Pharmaceuticals Corp. stock supported by strong fundamentalsPortfolio Risk Summary & Free Growth Oriented Trading Recommendations - newser.com
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phio Pharmaceuticals Corp Stock (PHIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 10 '25 |
Buy |
2.42 |
2,000 |
4,840 |
27,149 |
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
0.98%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):